The HUG completes the PertADO trial evaluating Pertagen®, a new recombinant pertussis vaccine, in adolescents in Switzerland. The Geneva University Hospitals (HUG) and BioNet-Asia (BioNet) announce that results of the PertADO Trial in Switzerland show that vaccination of adolescents with Pertagen®, a new recombinant pertussis vaccine developed by BioNet, induced a higher Pertussis Toxin (PT) response 28…